APTO
Aptose Biosciences
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 517.75M; Volume: 89.73K; AvgVol 3m: 954.26K; Beta: 1.57;
Cost estimate:
P/E: –; EPS: -0.61; EPS growth quarter/prev quarter: -54.30%;
EPS growth this year: 39.40%; EPS growth past 5 years: 4.80%;
EPS ttm: -0.61;
P/S: ; P/B: 5.67; P/Cashflow: 6.62; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -53.80%; ROE – return on equity: -58.10%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 20.40%; Insider Transactions:-2.14%;
Institutional Ownership: 35.10%; Institutional Transactions: 0.77%;
Data update: 07/10/2020.